Eye blood flow may reveal glaucoma before vision loss

NCT ID NCT05344274

Recruiting now Diagnosis Sponsor: University of Maryland, Baltimore Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether measuring blood flow in the retina can help detect early glaucoma. Researchers will use special dyes and imaging to see how blood vessels respond to oxygen. The goal is to find a reliable early warning sign for the disease. About 90 adults with early glaucoma or healthy eyes will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Indocyanine green dye and oxygen supplementation
What this could lead to: If successful, this could lead to a simple, non-invasive test to detect glaucoma earlier, potentially preventing vision loss.
What could go wrong: This is a small, early-phase study focused on finding a biomarker, not a treatment. The results may not translate into a widely usable test.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLAUCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glaucoma open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLAUCOMA

Contacts and locations

Locations

Food and Drug Administration (FDA)
RECRUITING

Silver Spring, Maryland, 20903, United States
University of Maryland Faculty Physicians, Inc
RECRUITING

Baltimore, Maryland, 21201, United States
University of Maryland Medical Center
RECRUITING

Baltimore, Maryland, 21201, United States
University of Maryland, Baltimore
RECRUITING

Baltimore, Maryland, 21201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.